CareDx (NASDAQ:CDNA) Given New $22.00 Price Target at Craig Hallum

CareDx (NASDAQ:CDNAFree Report) had its target price hoisted by Craig Hallum from $15.00 to $22.00 in a research note issued to investors on Friday morning, Benzinga reports. Craig Hallum currently has a buy rating on the stock.

CDNA has been the topic of several other research reports. The Goldman Sachs Group raised their price target on shares of CareDx from $10.00 to $14.00 and gave the stock a buy rating in a research note on Monday, May 13th. Raymond James downgraded shares of CareDx from an outperform rating to a market perform rating in a research note on Monday, May 13th. Stephens raised their price target on shares of CareDx from $15.00 to $18.00 and gave the stock an overweight rating in a research note on Monday, May 13th. HC Wainwright reissued a neutral rating on shares of CareDx in a research report on Wednesday. Finally, StockNews.com raised shares of CareDx from a hold rating to a buy rating in a research report on Friday, May 10th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of Moderate Buy and an average target price of $16.50.

Get Our Latest Stock Report on CareDx

CareDx Price Performance

Shares of CareDx stock traded up $0.72 during trading on Friday, hitting $15.50. The stock had a trading volume of 883,691 shares, compared to its average volume of 979,504. The firm’s fifty day simple moving average is $10.11 and its 200-day simple moving average is $9.86. CareDx has a 12 month low of $4.80 and a 12 month high of $16.15.

CareDx (NASDAQ:CDNAGet Free Report) last released its earnings results on Wednesday, February 28th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($1.97). The firm had revenue of $65.57 million during the quarter, compared to the consensus estimate of $63.66 million. CareDx had a negative return on equity of 55.08% and a negative net margin of 66.59%. CareDx’s revenue was down 20.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.34) EPS. As a group, equities research analysts forecast that CareDx will post -1.59 EPS for the current year.

Institutional Trading of CareDx

Institutional investors have recently modified their holdings of the company. Headlands Technologies LLC bought a new stake in shares of CareDx in the 4th quarter valued at about $50,000. WINTON GROUP Ltd bought a new stake in shares of CareDx in the 3rd quarter valued at about $72,000. Nisa Investment Advisors LLC boosted its holdings in shares of CareDx by 442.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,440 shares of the company’s stock valued at $77,000 after buying an additional 5,253 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of CareDx by 23.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,751 shares of the company’s stock valued at $82,000 after buying an additional 2,211 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC bought a new stake in shares of CareDx in the 3rd quarter valued at about $85,000.

CareDx Company Profile

(Get Free Report)

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

Further Reading

Analyst Recommendations for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.